A Randomized Double-Blind Placebo-Controlled Phase III Trial of Selegiline Monotherapy for Early Parkinson Disease. Issue 5 (September 2017)

• Record Type: Journal Article
• Authors: Mizuno, Yoshikuni; Hattori, Nobutaka; Kondo, Tomoyoshi; Nomoto, Masahiro; Origasa, Hideki; Takahashi, Ryosuke; Yamamoto, Mitsutoshi; Yanagisawa, Nobuo
• Is Part Of: Clinical neuropharmacology. Volume 40:Issue 5(2017)
• Publication Date: 2017-09
• Subjects: Parkinson disease -- treatment -- selegiline -- monotherapy -- UPDRS; Neuropharmacology -- Periodicals; 615.78
• DOI: 10.1097/WNF.0000000000000239
• Languages: English
• ISSNs: 0362-5664

Abstract

Abstract : Background: In Japan, selegiline has been approved for combination therapy with levodopa for Parkinson disease (PD). We conducted a trial of selegiline monotherapy for early PD. Methods: In this 12-week controlled phase III trial, a total of 292 subjects were randomized to receive placebo (n = 146) (full analysis set 140) or selegiline (n = 146) (full analysis set 139). The primary outcome measure was the change in the Unified Parkinson Disease Rating Scale part I + II + III total score from baseline to the final visit. Other secondary measures and a safety profile were evaluated. Results: Selegiline monotherapy reduced the primary outcome measure by −6.26 ± 7.86 compared with the placebo −3.14 ± 6.98 (mean ± SD, P = 0.0005 by analysis of covariance). There was no significant difference in the number of adverse events between the 2 groups ( P > 0.05). Conclusions: Selegiline monotherapy reduced the total Unified Parkinson Disease Rating Scale part I + II + III score and was well tolerated in Japanese patients with early PD.